Today at 12
MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new data about its lead clinical product candidate, PH-762, an INTASYL compound.
Preclinical studies demonstrate:
The data, authored by Melissa Maxwell, Linda Mahoney, and Dr. Mary Spellman, will be presented at the American Society of Gene and Cell Therapy (ASGCT) on May 8th in Baltimore, Maryland.
Presentation Details are as follows:Title:NTASYL PH-762: PD-1 Intratumoral ImmunotherapyAbstract Number774Session Title:Cancer-Immunotherapy and Cancer VaccinesAuthors:Melissa Maxwell, Linda Mahoney, Mary Spellman, M.D.
Date and Time:May 8, 2024 12:00 PM
Location:Exhibit Hall
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
the stock market is an introvert casino with fewer people on meth.
72Followers
40Following
420Visitors
Follow